Myalepta

Active substance

Metreleptine

Holder

Amryt Pharmaceuticals DAC

Statut

Running

Indication

Treatment of patients with generalized lipodystrophy or patients with partial lipodystrophy and uncontrollable metabolic disorders.

Public documents

Approbation

Information for the patient

Informed consent

Last update

20/03/2023

Last updated on 13/02/2024